Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market is estimated to be worth around USD 20.1 billion by 2030

Basic information
Date of placement
7
0
0
  • <p>Liquid Biopsy and Other
Non-Invasive Cancer Diagnostics Market is estimated to be worth around USD 20.1
billion by 2030</p> photo

Nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease. Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market, Forecast to 2030 The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments: Type of Tumor Marker · ctDNA · cfDNA · CTCs · Exosomes · Others Application · Diagnosis / Early Diagnosis · Patient Monitoring · Recurrence Monitoring Target Cancer Indication · Breast Cancer · Lung Cancer · Colorectal Cancer · Prostate Cancer · Bladder Cancer · Melanoma · Gastric Cancer · Pancreatic Cancer · Ovarian Cancer · Others End Users · Hospitals · Research Institutes · Others Key Geographical Regions · North America · Europe · Asia-Pacific · Rest of the World Get Latest Market Insights: Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market is estimated to be worth around USD 20.1 billion by 2030 The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers report features the following companies, which we identified to be key players in this domain: Key Players: · Amoy Diagnostics · DiaCarta · HaploX Biotechnology · NeoGenomics · QIAGEN · Swift Biosciences · Sysmex Inostics · Thermo Fisher Scientific Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Non-Invasive Cancer Screening and Diagnosis 5. Market Landscape 6. Company Profiles 7. Partnerships and Collaborations 8. Funding and Investment Analysis 9. Liquid Biopsy: Initiatives of Big Pharma Players 10. Key Acquisition Targets 11. Other Non-Invasive Cancer Diagnostics 12. Market Sizing and Opportunity Analysis 13. Survey Insights 14. Conclusion 15. Executive Insights 16. Appendix 1: Tabulated Data 17. Appendix 2: List of Companies and Organizations Request for Customization: Request Customization - Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers | Market Size | In About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected]

(0)
0.0
Dislike 0
ОТН 0
Like 0
 
Someone is typing...
I agree and close
x We use cookies to measure visitor statistics, personalize ads and customize the functionality of the site. You agree to this by using the website